You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

FDA expands use of J&J cancer drug

WASHINGTON — The Food and Drug Administration on Monday expanded its approval­ of Johnson & Johnson’s prostate cancer pill, Zytiga, for men with an earlier stage of the disease.

The agency said Zytiga is now approved for late-stage prostate cancer patients who have not yet received chemotherapy, based on study results showing it can extend life by up to five months when taken by men in that group.

Continue reading below

The FDA had in April 2011 approved the drug for men with prostate cancer who have already taken the chemotherapy drug docetaxel.

Zytiga works by decreasing the male hormone testosterone. Testosterone stimulates the growth of prostate tumors, and treatment often includes administering drugs aimed at cutting the body’s testosterone production.

In a study, the typical patient taking Zytiga survived five months longer than the typical patient taking a fake pill, or placebo.

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week